• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 30, 2023 at 11:12: PM
via With approvals for Aduhelm (aducanumab) and Leqembi (lecanemab) under its belt, Biogen presented data Wednesday for an Alzheimer’s disease therapy with a different target at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2023) in Stockholm, Sweden.

article source
 

<



Similar threads

cafead
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai, Biogen&#039;s Leqembi nabs UK nod, but reimbursement remains elusive
Replies
0
Views
33
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen sued for alleged PBM kickbacks scheme to boost Tecfidera in wake of generics
Replies
0
Views
73
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Driven by Leqembi, Biogen beats Q2 expectations, raises full-year outlook
Replies
0
Views
36
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After EU setback, Eisai/Biogen build case for Leqembi
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote